

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Disease models</b>			
<p>Mouse model of hemolytic anemia induced by malaria drugs</p>	<p>A mouse model of hemolytic anemia could be useful for evaluating the tolerability of antimalarial compounds. Marketed antimalarial 8-aminoquinoline (8-AQ) compounds cause hemolytic anemia in patients with inherited glucose-6-phosphate dehydrogenase (G6PD) deficiency. In immunocompromised mice engrafted with human <i>G6PD</i>-deficient erythrocytes, compared with mice engrafted with normal erythrocytes, the 8-AQ compound primaquine increased hemolysis and anemia. Next steps include collaborating with Medicines for Malaria Venture, a philanthropic organization, to test the tolerability of malaria therapeutic candidates in the model.</p>	<p>Unpatented; licensing status not applicable</p>	<p>Rochford, R. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 7, 2013; doi:10.1073/pnas.1310402110  <b>Contact:</b> Rosemary Rochford, SUNY Upstate Medical University, Syracuse, N.Y.                      e-mail: <a href="mailto:rochforr@upstate.edu">rochforr@upstate.edu</a></p>
	<p><b>SciBX 6(45); doi:10.1038/scibx.2013.1303</b>                      Published online Nov. 21, 2013</p>		